Related Experiment Video
Updated: May 28, 2026

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
Renal scintigraphy predicts global cardiovascular risk in hypertensive subjects with normal serum creatinine levels
Alberto Mazza1, Lucia Rampin, Domenico Montemurro
1Department of Internal Medicine, 'Santa Maria della Misericordia' Hospital of Rovigo, Italy.
Insights
Renal scintigraphy aids cardiovascular risk stratification in hypertensive individuals over 55. It identifies previously unknown stage III chronic kidney disease (CKD), significantly impacting risk assessment.
Area of Science:
- Nephrology
- Cardiology
- Diagnostic Imaging
Background:
- Investigates cardiovascular (CV) risk stratification in hypertensive subjects (HTs) without CV disease or renal dysfunction.
- Focuses on normoalbuminuric, non-diabetic HTs aged 55-75 years.
- Examines the utility of renal scintigraphy in identifying early-stage chronic kidney disease (CKD).
Purpose of the Study:
- To evaluate the role of renal scintigraphy in cardiovascular risk stratification.
- To compare CKD diagnosis methods (renal scintigraphy, MDRD, Cockcroft-Gault) and their impact on CV risk.
- To identify predictors of stage III CKD in hypertensive patients.
Main Methods:
- Cross-sectional study of 200 hypertensive subjects (HTs).
- Glomerular filtration rate (GFR) measured via technetium-99m-diethylene triamine pentacetic acid clearance during renal scintigraphy.
- Target organ damage (TOD) assessed by echocardiography and carotid ultrasonography; CKD defined as GFR < 60 ml/min/1.73 m².
Main Results:
- 38% of participants had previously undiagnosed stage III CKD.
- Hypertension history, albuminuria, smoking, and pulse pressure predicted CKD in men.
- Renal scintigraphy identified higher TOD prevalence and significantly altered CV risk stratification compared to other methods.
Conclusions:
- Renal scintigraphy is crucial for risk stratification in hypertensive patients over 55.
- It aids in detecting unknown stage III CKD, thereby refining cardiovascular risk assessment.
- Pulse pressure is a key predictor of stage III CKD in this population.
Abstract:
BACKGROUND. This cross-sectional study investigates the role of renal scintigraphy on cardiovascular (CV) risk stratification in normoalbuminuric, non-diabetic hypertensive subjects (HTs) free from CV disease and renal dysfunction. METHODS. In 200 HTs aged 55-75 years, glomerular filtration rate (GFR) was measured by technetium-99m-diethylene triamine pentacetic acid clearance during renal scintigraphy. Stage III chronic kidney disease (CKD) was defined as GFR < 60 ml/min/1.73 m(2). For comparing the impact of different methods for CKD diagnosis on CV risk stratification, CKD was also considered as GFR estimated by the Modification of Diet in Renal Disease (MDRD) equation and Cockcroft-Gault's formula. Target organ damage (TOD) was assessed by echocardiography and carotid ultrasonography. Gender-specific odds ratio (OR) with 95% confidence intervals for CKD were derived from a multiple stepwise logistic regression analysis. Global CV risk was stratified according to routine examinations, TOD and CKD. RESULTS. In 38% of cases, an unknown stage III CKD was found. Independent of age, CKD was predicted by history of hypertension (OR = 1.69, p = 0.0001), albuminuria (OR = 1.25, p = 0.0001), smoking (OR = 1.85, p = 0.028) and pulse pressure (OR = 1.21, p = 0.019) in men only. Men had an increased risk of CKD (OR = 2.62, p = 0.002) in comparison with women. Prevalence of TOD was significantly higher only in HTs having CKD diagnosed by renal scintigraphy; TOD and CKD assessment added to classic risk factors modified the CV risk stratification from low-moderate to high and very high. CONCLUSIONS. Renal scintigraphy is an important aid in risk stratification and should be performed in HTs aged >55 years. Pulse pressure was the main blood pressure component that predicted the risk of stage III CKD.
Related Concept Videos
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Serum Studies: Renal Function Tests
Acute Kidney Injury IV: Diagnostic Studies and Prevention
